Otegal150 mg

Otegal is an oral tetrazole antifungal approved for a single, specific indication:

• FDA-approved use: To reduce the incidence of recurrent episodes of vulvovaginal candidiasis (RVVC, commonly known as recurrent vaginal yeast infection) in females who are not of reproductive potential and who have a history of recurrent yeast infections (defined as three or more episodes in the past 12 months).

Otegal is not indicated for the treatment of an acute, active episode of vulvovaginal candidiasis; it is used only for reducing the frequency of future recurrences after the acute infection has been appropriately treated. There are currently no other guideline-supported, adjunct, or accepted off-label uses established for Otegal.

Each capsule of Oteseconazole contains oteseconazole as the active pharmaceutical ingredient, formulated with standard pharmaceutical excipients for oral administration. Strength and exact excipient composition may vary by manufacturer/brand; refer to the specific product packaging/leaflet for complete details.

Otegal is a novel oral tetrazole antifungal agent that selectively inhibits fungal enzymes involved in cell membrane synthesis. It was developed specifically to reduce the recurrence of vulvovaginal candidiasis rather than to treat active fungal infections. A distinguishing pharmacologic feature of Otegal is its very long elimination half-life, allowing an initial short loading course followed by a once-weekly maintenance dosing schedule.

Otegal belongs to the tetrazole class of antifungal agents, a newer subclass distinct from the older triazole/imidazole azole antifungals, designed to selectively target fungal (rather than human) cytochrome P450 enzymes.

Oteseconazole works by selectively inhibiting fungal lanosterol 14α-demethylase (CYP51), an enzyme required for ergosterol synthesis, a critical component of the fungal cell membrane. By blocking ergosterol production, Oteseconazole disrupts fungal cell membrane integrity and inhibits growth of Candida species. Its tetrazole metal-binding group gives it high selectivity for the fungal CYP51 enzyme over human cytochrome P450 enzymes compared with older azole antifungals, which may reduce certain off-target drug interaction risks, although clinically relevant CYP interactions still occur (see Drug Interactions).

Oteseconazole has an unusually long terminal elimination half-life (measured in months), which permits an initial loading-dose regimen followed by once-weekly maintenance dosing, but also means systemic exposure can persist for a prolonged period after the last dose is taken.

Otegal capsules should be swallowed whole with a meal. Do not crush or chew the capsules. Maintenance doses should be taken on the same day each week to maintain a consistent schedule.

Otegal is metabolized by and interacts with several cytochrome P450 enzymes and transporters. Clinically significant interactions include:

• CYP3A4 substrates: Otegal may increase plasma concentrations of drugs metabolized by CYP3A4, potentially increasing their effects or toxicity; concurrent use with sensitive CYP3A4 substrates that have narrow therapeutic windows should be approached with caution and physician oversight.
• CYP2C9 substrates (e.g., warfarin): Otegal may inhibit CYP2C9, increasing exposure to CYP2C9 substrates; increased monitoring (e.g., INR for warfarin) is advised.
• BCRP transporter substrates (e.g., rosuvastatin): Otegal may increase plasma levels of BCRP substrate drugs; dose adjustment or monitoring for toxicity may be needed.

Inform your physician of all prescription, over-the-counter, and herbal medicines being used before starting Otegal.

The most commonly reported adverse effects of Otegal in clinical trials include headache and nausea. Other adverse effects reported include:

• Back pain
• Abdominal discomfort
• Fatigue

Most adverse effects reported have been mild to moderate. Given that Otegal is a relatively novel medicine, long-term safety data remain limited, and patients should report any unusual or persistent symptoms to their physician.

Otegal is contraindicated in pregnancy and in females of reproductive potential (see Contraindications) due to demonstrated embryo-fetal toxicity in animal studies and its unusually prolonged systemic exposure. Because of the very long elimination half-life, systemic exposure to Otegal can persist for an extended period after the last dose, which is an important consideration for any future pregnancy planning even after treatment has been discontinued. There is no adequate data on the presence of Otegal in human breast milk; breastfeeding is not recommended during and following treatment given the prolonged systemic exposure, and a physician should be consulted regarding the appropriate interval before breastfeeding may be considered safe.

Otegal should only be prescribed after confirming the patient is not of reproductive potential, given the embryo-fetal risk described in Contraindications.

• Prolonged systemic exposure: Due to its very long elimination half-life, Otegal can remain in the body for an extended period after the last dose; this is relevant to future pregnancy planning and to potential drug interactions that may persist after stopping treatment.
• Not for acute infection: Otegal is indicated only for reducing the recurrence of vulvovaginal candidiasis, not for treating an active, acute episode.
• Limited long-term data: As a relatively novel antifungal, long-term safety experience with Otegal outside of clinical trials remains limited; use strictly according to the approved indication and under medical supervision.

Take Otegal exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

There is limited clinical experience with Otegal overdose. In case of a suspected overdose, seek immediate medical attention or contact a poison control center/emergency services. Treatment of overdose should be symptomatic and supportive, as directed by a physician; there is no specific antidote for Otegal overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: No dedicated dose adjustment for Otegal has been well established; use with caution and physician guidance.

Hepatic impairment: Use Otegal with caution; data in patients with severe hepatic impairment are limited.

Elderly: Otegal is indicated for females not of reproductive potential, which may include postmenopausal women; no specific dose adjustment is established for elderly patients based on age alone.

Pediatric patients: See Pediatric Uses.

The complete treatment course with Otegal is 12 weeks: a 2-day oral loading dose regimen (Day 1 and Day 2) followed by once-weekly maintenance dosing for 11 weeks starting on Day 14. The full course should be completed as prescribed even if symptoms of recurrent yeast infection do not occur during treatment, since the purpose of Otegal is preventive.

Oteseconazole belongs to the tetrazole antifungal drug class, a structurally distinct subclass of azole antifungals developed for greater selectivity toward fungal versus human CYP enzymes.

Oteseconazole selectively inhibits fungal lanosterol 14α-demethylase (CYP51), blocking ergosterol biosynthesis, which is essential for fungal cell membrane structure and function. This disruption of the fungal cell membrane inhibits growth of Candida species responsible for vulvovaginal candidiasis, thereby reducing the likelihood of recurrence when used as directed.

The safety and efficacy of Otegal have not been established in pediatric patients. Otegal is approved for use in females who are not of reproductive potential, which by definition excludes use in children and adolescents of reproductive potential; it should not be used in pediatric patients outside of this defined population, and only under specialist medical guidance if ever considered.